Compare Alcon AG (ALC) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Endeavour Silver Corp — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Endeavour Silver Corp trades at $7.7 (market cap $2.37B). The key difference: Alcon AG is far larger — about 13.8× Endeavour Silver Corp's market cap, and Alcon AG pays a 0.54% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| ALC | EXK | |
|---|---|---|
Market Cap | $32.69B | $2.37B |
Sector | Health | Basic Materials |
52-Week High | $92.22 | $14.12 |
52-Week Low | $62.02 | $4.84 |
Enterprise Value | $36.28B | $2.38B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Endeavour Silver (EXK) trades at $8.51, down 0.58% on the day, with a neutral technical signal and bearish moving averages. The company reported strong Q1 2026 results with earnings of $0.21 per share beating expectations, driven by record production. However, full-year 2025 showed a net loss of $119.10 million despite revenue growth. Recent news highlights high-grade mineralization discoveries at its Terronera mine, supporting future production potential.
The outlook is mixed: analyst consensus is strongly bullish (78.57% buy ratings), but profitability remains a concern with negative margins. Key risks include execution on growth projects and silver price volatility. Upside catalysts hinge on sustained operational improvements and favorable commodity markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
